Impact Partnership Wealth’s Adicet Bio ACET Stock Holding History

Impact Partnership Wealth’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4	Closed	-$163	–	991
2023 Q2	$163	Buy	+4	New	+$353	﹤0.01%	888

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Impact Partnership Wealth's ACET Position: Q3 2023 in Review

Impact Partnership Wealth sold out of Adicet Bio (ACET) in Q3 2023, closing a stake of 4 shares — an estimated $163 sold.

Impact Partnership Wealth first reported a position in ACET in Q2 2023 and held it in 1 quarter. The position peaked at $163 in Q2 2023. 83 funds tracked by Wall St. Rank hold ACET as of Q3 2023.

Impact Partnership Wealth reported no remaining Adicet Bio position as of Q3 2023 after selling out during the quarter.
Impact Partnership Wealth sold 4 Adicet Bio shares in Q3 2023, an estimated $163.
Impact Partnership Wealth first reported a position in Adicet Bio in Q2 2023 and held it in 1 quarter.
Impact Partnership Wealth's Adicet Bio position peaked at $163 in Q2 2023.
83 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2023.

Based on Impact Partnership Wealth's 13F filing for Q3 2023, filed 17 Oct 2023.